Immunosuppression-related neurological disorders in kidney transplantation.
Immunosuppressive drugs
Nervous system
Neurological disorders
Renal transplantation
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
08
07
2020
accepted:
27
12
2020
pubmed:
23
1
2021
medline:
19
8
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
A large number of neurological disorders can affect renal transplant recipients, potentially leading to disabling or life-threatening complications. Prevention, early diagnosis and appropriate management of these conditions are critical to avoid irreversible lesions. A pivotal role in the pathogenesis of common post-transplant neurological disorders is played by immunosuppressive therapy. The most frequently administered regimen consists of triple immunosuppression, which comprises a calcineurin inhibitor (CNI), a purine synthesis inhibitor and glucocorticoids. Some of these immunosuppressive drugs may lead to neurological signs and symptoms through direct neurotoxic effects, and all of them may be responsible for the development of tumors or opportunistic infections. In this review, after a brief summary of neurotoxic pathogenetic mechanisms encompassing recent advances in the field, we focus on the clinical presentation of more common and severe immunosuppression-related neurological complications, classifying them by characteristics of urgency and anatomic site. Our goal is to provide a general framework that addresses such clinical issues with a multidisciplinary approach, as these conditions require.
Identifiants
pubmed: 33481222
doi: 10.1007/s40620-020-00956-1
pii: 10.1007/s40620-020-00956-1
pmc: PMC8036223
doi:
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-555Références
Rizzo MA, Frediani F, Granata A et al (2012) Neurological complications of hemodialysis: state of the art. J Nephrol 25:170–182. https://doi.org/10.5301/jn.5000087
doi: 10.5301/jn.5000087
pubmed: 22241633
Ponticelli C, Glassock RJ (2019) Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol 32:851–870. https://doi.org/10.1007/s40620-019-00602-5
doi: 10.1007/s40620-019-00602-5
pubmed: 30927190
Dohgu S, Yamauchi A, Nakagawa S et al (2004) Nitric oxide mediates cyclosporine-induced impairment of the blood-brain barrier in cocultures of mouse brain endothelial cells and rat astrocytes. Eur J Pharmacol 505:51–59. https://doi.org/10.1016/j.ejphar.2004.10.027
doi: 10.1016/j.ejphar.2004.10.027
pubmed: 15556136
Kochi S, Takanaga H, Matsuo H et al (2000) Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin a and tacrolimus. Life Sci 66:2255–2260. https://doi.org/10.1016/S0024-3205(00)00554-3
doi: 10.1016/S0024-3205(00)00554-3
pubmed: 10855946
Stoltenburg-Didinger G, Boegner F (1992) Glia toxicity in dissociation cell cultures induced by cyclosporine. Neurotoxicology 13:179–184
pubmed: 1324448
McDonald JW, Goldberg MP, Gwag BJ et al (1996) Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol 40:750–758. https://doi.org/10.1002/ana.410400511
doi: 10.1002/ana.410400511
pubmed: 8957016
Jin KB, Choi HJ, Kim HT et al (2008) The production of reactive oxygen species in tacrolimus-treated glial cells. Transplant Proc 40:2680–2681. https://doi.org/10.1016/j.transproceed.2008.08.033
doi: 10.1016/j.transproceed.2008.08.033
pubmed: 18929834
Sander M, Lyson T, Thomas GD, Victor RG (1996) Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 9:121S-138S. https://doi.org/10.1016/0895-7061(96)00288-9
doi: 10.1016/0895-7061(96)00288-9
pubmed: 8931845
Gold BG (1997) FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 15:285–306. https://doi.org/10.1007/BF02740664
doi: 10.1007/BF02740664
pubmed: 9457703
Arnold R, Pussell BA, Pianta TJ et al (2013) Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 13:2426–2432. https://doi.org/10.1111/ajt.12324
doi: 10.1111/ajt.12324
pubmed: 23841745
Hoorn EJ, Walsh SB, McCormick JA et al (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25:269–275. https://doi.org/10.5301/jn.5000174
doi: 10.5301/jn.5000174
pubmed: 22573529
pmcid: 4048819
Uchino H, Minamikawa-Tachino R, Kristián T et al (2002) Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol Dis 10:219–233. https://doi.org/10.1006/nbdi.2002.0514
doi: 10.1006/nbdi.2002.0514
pubmed: 12270685
Bochelen D, Rudin M, Sauter A (1999) Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 288:653–659
pubmed: 9918571
Nito C, Ueda M, Inaba T et al (2011) FK506 ameliorates oxidative damage and protects rat brain following transient focal cerebral ischemia. Neurol Res 33:881–889. https://doi.org/10.1179/1743132811Y.0000000019
doi: 10.1179/1743132811Y.0000000019
pubmed: 22004713
Partoazar A, Nasoohi S, Rezayat SM et al (2017) Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat. Fundam Clin Pharmacol 31:185–193. https://doi.org/10.1111/fcp.12244
doi: 10.1111/fcp.12244
pubmed: 27616018
Furuichi Y, Katsuta K, Maeda M et al (2003) Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res 965:137–145. https://doi.org/10.1016/s0006-8993(02)04151-3
doi: 10.1016/s0006-8993(02)04151-3
pubmed: 12591130
Malouitre S, Dube H, Selwood D, Crompton M (2009) Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J 425:137–148. https://doi.org/10.1042/BJ20090332
doi: 10.1042/BJ20090332
pubmed: 19832699
pmcid: 2860807
Panettieri RA, Schaafsma D, Amrani Y et al (2019) Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci 40:38–49. https://doi.org/10.1016/j.tips.2018.11.002
doi: 10.1016/j.tips.2018.11.002
pubmed: 30497693
Joëls M (2018) Corticosteroids and the brain. J Endocrinol 238:R121–R130. https://doi.org/10.1530/JOE-18-0226
doi: 10.1530/JOE-18-0226
pubmed: 29875162
Moisiadis VG, Matthews SG (2014) Glucocorticoids and fetal programming part 1: Outcomes. Nat Rev Endocrinol 10:391–402. https://doi.org/10.1038/nrendo.2014.73
doi: 10.1038/nrendo.2014.73
pubmed: 24863382
Sousa N, Almeida OFX (2012) Disconnection and reconnection: the morphological basis of (mal)adaptation to stress. Trends Neurosci 35:742–751. https://doi.org/10.1016/j.tins.2012.08.006
doi: 10.1016/j.tins.2012.08.006
pubmed: 23000140
Bockaert J, Marin P (2015) mTOR in brain physiology and pathologies. Physiol Rev 95:1157–1187. https://doi.org/10.1152/physrev.00038.2014
doi: 10.1152/physrev.00038.2014
pubmed: 26269525
Ramanathan A, Schreiber SL (2009) Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci USA 106:22229–22232. https://doi.org/10.1073/pnas.0912074106
doi: 10.1073/pnas.0912074106
pubmed: 20080789
Wang Y, Barbaro MF, Baraban SC (2006) A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett 401:35–39. https://doi.org/10.1016/j.neulet.2006.03.011
doi: 10.1016/j.neulet.2006.03.011
pubmed: 16677760
Jin M-M, Wang F, Qi D et al (2018) A critical role of autophagy in regulating microglia polarization in neurodegeneration. Front Aging Neurosci 10:378. https://doi.org/10.3389/fnagi.2018.00378
doi: 10.3389/fnagi.2018.00378
pubmed: 30515090
pmcid: 6256089
Pignataro G, Capone D, Polichetti G et al (2011) Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Curr Opin Pharmacol 11:378–394. https://doi.org/10.1016/j.coph.2011.05.003
doi: 10.1016/j.coph.2011.05.003
pubmed: 21646048
Klawitter J, Gottschalk S, Hainz C et al (2010) Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol 23:608–619. https://doi.org/10.1021/tx900351q
doi: 10.1021/tx900351q
pubmed: 20148532
pmcid: 2841482
Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834–4840. https://doi.org/10.1182/blood-2008-10-186999
doi: 10.1182/blood-2008-10-186999
pubmed: 19264918
pmcid: 2686134
Kapoor T, Mahadeshwar P, Hui-Yuen J et al (2020) Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. Lupus Sci Med. https://doi.org/10.1136/lupus-2020-000388
doi: 10.1136/lupus-2020-000388
pubmed: 32513809
pmcid: 7282388
Toyoda M, Thomas D, Ahn G et al (2015) JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Infect Dis 17:838–847. https://doi.org/10.1111/tid.12465
doi: 10.1111/tid.12465
pubmed: 26437369
Avivi I, Chakrabarti S, Kottaridis P et al (2004) Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 34:137–142. https://doi.org/10.1038/sj.bmt.1704538
doi: 10.1038/sj.bmt.1704538
pubmed: 15235576
Vincenti F, Blancho G, Durrbach A et al (2010) Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 21:1587–1596. https://doi.org/10.1681/ASN.2009111109
doi: 10.1681/ASN.2009111109
pubmed: 20634298
pmcid: 3013525
Estol CJ, Lopez O, Brenner RP, Martinez AJ (1989) Seizures after liver transplantation: a clinicopathologic study. Neurology 39:1297–1301. https://doi.org/10.1212/wnl.39.10.1297
doi: 10.1212/wnl.39.10.1297
pubmed: 2797452
Sevmis S, Karakayali H, Emiroglu R et al (2007) Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc 39:1211–1213. https://doi.org/10.1016/j.transproceed.2007.02.049
doi: 10.1016/j.transproceed.2007.02.049
pubmed: 17524935
Yardimci N, Colak T, Sevmis S et al (2008) Neurologic complications after renal transplant. Exp Clin Transplant 6:224–228
pubmed: 18954301
Odeh M, Lavy A, Stermer E (2003) Hydrocortisone-induced convulsions. J Toxicol Clin Toxicol 41:995–997. https://doi.org/10.1081/clt-120026524
doi: 10.1081/clt-120026524
pubmed: 14705848
Ponticelli C, Campise MR (2005) Neurological complications in kidney transplant recipients. J Nephrol 18:521–528
pubmed: 16299677
Nankivell BJ, Lau SG, Chapman JR et al (2000) Progression of macrovascular disease after transplantation. Transplantation 69:574–581. https://doi.org/10.1097/00007890-200002270-00019
doi: 10.1097/00007890-200002270-00019
pubmed: 10708114
Shoskes A, Wilson R (2019) Neurologic complications of kidney transplantation. Transl Androl Urol 8:164–172. https://doi.org/10.21037/tau.2018.08.11
doi: 10.21037/tau.2018.08.11
pubmed: 31080777
pmcid: 6503229
Kazory A, Ducloux D (2004) Acquired hypercoagulable state in renal transplant recipients. Thromb Haemost 91:646–654. https://doi.org/10.1160/TH03-09-0568
doi: 10.1160/TH03-09-0568
pubmed: 15045124
Satterthwaite R, Aswad S, Sunga V et al (1998) Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65:446–449. https://doi.org/10.1097/00007890-199802150-00030
doi: 10.1097/00007890-199802150-00030
pubmed: 9484771
Liu J, Liu D, Li J et al (2017) Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a meta-analysis of randomized controlled trials. PLoS ONE 12:e0170246. https://doi.org/10.1371/journal.pone.0170246
doi: 10.1371/journal.pone.0170246
pubmed: 28107397
pmcid: 5249216
Wijdicks EF, Torres VE, Schievink WI, Sterioff S (1999) Cerebral hemorrhage in recipients of renal transplantation. Mayo Clin Proc 74:1111–1112. https://doi.org/10.4065/74.11.1111
doi: 10.4065/74.11.1111
pubmed: 10560598
Willicombe M, Kumar N, Goodall D et al (2015) Incidence, risk factors, and outcomes of stroke post-transplantation in patients receiving a steroid sparing immunosuppression protocol. Clin Transplant 29:18–25. https://doi.org/10.1111/ctr.12476
doi: 10.1111/ctr.12476
pubmed: 25307366
Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14:914–925. https://doi.org/10.1016/S1474-4422(15)00111-8
doi: 10.1016/S1474-4422(15)00111-8
pubmed: 26184985
Bartynski WS, Tan HP, Boardman JF et al (2008) Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 29:924–930. https://doi.org/10.3174/ajnr.A0960
doi: 10.3174/ajnr.A0960
pubmed: 18272559
Roth C, Ferbert A (2011) The posterior reversible encephalopathy syndrome: what’s certain, what’s new? Pract Neurol 11:136–144. https://doi.org/10.1136/practneurol-2011-000010
doi: 10.1136/practneurol-2011-000010
pubmed: 21551107
Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions—principles and clinical implications. Curr Neuropharmacol 8:254–267. https://doi.org/10.2174/157015910792246254
doi: 10.2174/157015910792246254
pubmed: 21358975
pmcid: 3001218
Shepard PW, St Louis EK (2012) Seizure treatment in transplant patients. Curr Treat Options Neurol 14:332–347. https://doi.org/10.1007/s11940-012-0180-y
doi: 10.1007/s11940-012-0180-y
pubmed: 22660960
pmcid: 3656593
Chtioui H, Zimmermann A, Dufour J-F (2005) Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation. Liver Transpl 11:588–590. https://doi.org/10.1002/lt.20425
doi: 10.1002/lt.20425
pubmed: 15838866
Wu Q, Marescaux C, Wolff V et al (2010) Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 64:169–177. https://doi.org/10.1159/000319032
doi: 10.1159/000319032
pubmed: 20699617
Berger JR, Neltner J, Smith C, Cambi F (2014) Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Mult Scler Relat Disord 3:728–731. https://doi.org/10.1016/j.msard.2014.08.004
doi: 10.1016/j.msard.2014.08.004
pubmed: 25891552
Touhami S, Arzouk N, Darugar A et al (2014) Everolimus-induced posterior reversible encephalopathy syndrome and bilateral optic neuropathy after kidney transplantation. Transplantation 98:e102-104. https://doi.org/10.1097/TP.0000000000000551
doi: 10.1097/TP.0000000000000551
pubmed: 25955341
Mohammadi MH, Salarzaei M, Parooie F (2019) Neurological complications after renal transplantation: a systematic review and meta-analysis. Ther Apher Dial 23:518–528. https://doi.org/10.1111/1744-9987.12838
doi: 10.1111/1744-9987.12838
pubmed: 31090191
Navarro D, San-Juan R, Manuel O et al (2017) Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: an ESGICH survey. Transpl Infect Dis. https://doi.org/10.1111/tid.12773
doi: 10.1111/tid.12773
pubmed: 28859257
Anesi JA, Baddley JW (2016) Approach to the solid organ transplant patient with suspected fungal infection. Infect Dis Clin N Am 30:277–296. https://doi.org/10.1016/j.idc.2015.10.001
doi: 10.1016/j.idc.2015.10.001
Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467–480. https://doi.org/10.1016/S1474-4422(18)30040-1
doi: 10.1016/S1474-4422(18)30040-1
pubmed: 29656742
Medrano C, Vergez F, Mengelle C et al (2019) Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerging Infect Dis 25:2145–2147. https://doi.org/10.3201/eid2511.190705
doi: 10.3201/eid2511.190705
pmcid: 6810212
Ohara H, Kataoka H, Nakamichi K et al (2014) Favorable outcome after withdrawal of immunosuppressant therapy in progressive multifocal leukoencephalopathy after renal transplantation: case report and literature review. J Neurol Sci 341:144–146. https://doi.org/10.1016/j.jns.2014.03.048
doi: 10.1016/j.jns.2014.03.048
pubmed: 24746292
Muftuoglu M, Olson A, Marin D et al (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379:1443–1451. https://doi.org/10.1056/NEJMoa1801540
doi: 10.1056/NEJMoa1801540
pubmed: 30304652
pmcid: 6283403
Bugelski PJ, Achuthanandam R, Capocasale RJ et al (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:499–521. https://doi.org/10.1586/eci.09.31
doi: 10.1586/eci.09.31
pubmed: 20477639
Jackowiak E, Shah N, Chen H et al (2019) A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: clinical, pathological, and radiographic features. Transpl Infect Dis 21:e13162. https://doi.org/10.1111/tid.13162
doi: 10.1111/tid.13162
pubmed: 31419376
Perantie DC, Brown ES (2002) Corticosteroids, immune suppression, and psychosis. Curr Psychiatry Rep 4:171–176. https://doi.org/10.1007/s11920-002-0023-8
doi: 10.1007/s11920-002-0023-8
pubmed: 12003678
Dobbels F, Wong S, Min Y et al (2014) Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials. Transplantation 98:960–968. https://doi.org/10.1097/TP.0000000000000159
doi: 10.1097/TP.0000000000000159
pubmed: 24831918
Jagadeesh D, Woda BA, Draper J, Evens AM (2012) Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 13:122–136. https://doi.org/10.1007/s11864-011-0177-x
doi: 10.1007/s11864-011-0177-x
pubmed: 22241590
Piotrowski PC, Lutkowska A, Tsibulski A et al (2017) Neurologic complications in kidney transplant recipients. Folia Neuropathol 55:86–109. https://doi.org/10.5114/fn.2017.68577
doi: 10.5114/fn.2017.68577
pubmed: 28677367
Morscio J, Tousseyn T (2016) Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant 6:505–516. https://doi.org/10.5500/wjt.v6.i3.505
doi: 10.5500/wjt.v6.i3.505
pubmed: 27683629
pmcid: 5036120
Alnahdi MA, Al Malik YM (2019) Delayed tacrolimus-induced optic neuropathy. Neurosciences (Riyadh) 24:324–326. https://doi.org/10.17712/nsj.2019.4.20190022
doi: 10.17712/nsj.2019.4.20190022
Rasool N, Boudreault K, Lessell S et al (2018) Tacrolimus optic neuropathy. J Neuroophthalmol 38:160–166. https://doi.org/10.1097/WNO.0000000000000635
doi: 10.1097/WNO.0000000000000635
pubmed: 29420328
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36:123–133. https://doi.org/10.1159/000324710
doi: 10.1159/000324710
pubmed: 21422765
pmcid: 5703046
Myers SE, Williams SF (1994) Guillain-Barré syndrome after autologous bone marrow transplantation for breast cancer: report of two cases. Bone Marrow Transplant 13:341–344
pubmed: 8199578
Yoshida T, Ueki Y, Suzuki T et al (2016) Guillain-Barré syndrome after allogeneic bone marrow transplantation: case report and literature review. eNeurologicalSci 4:52–55. https://doi.org/10.1016/j.ensci.2016.08.001
doi: 10.1016/j.ensci.2016.08.001
pubmed: 29430549
pmcid: 5803090
El-Sabrout RA, Radovancevic B, Ankoma-Sey V, Van Buren CT (2001) Guillain-Barré syndrome after solid organ transplantation. Transplantation 71:1311–1316. https://doi.org/10.1097/00007890-200105150-00023
doi: 10.1097/00007890-200105150-00023
pubmed: 11397969
Ostman C, Chacko B (2019) Guillain-Barré syndrome post renal transplant: a systematic review. Transpl Infect Dis 21:e13021. https://doi.org/10.1111/tid.13021
doi: 10.1111/tid.13021
pubmed: 30403433
van der Zwan M, Hesselink DA, Brusse E et al (2020) Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000000721
doi: 10.1212/NXI.0000000000000721
pubmed: 32299841
pmcid: 7188471
Barnett MH, Pollard JD, Davies L, McLeod JG (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21:454–460. https://doi.org/10.1002/(sici)1097-4598(199804)21:4%3c454::aid-mus3%3e3.0.co;2-8
doi: 10.1002/(sici)1097-4598(199804)21:4<454::aid-mus3>3.0.co;2-8
pubmed: 9533779
Nieto-Ríos JF, Zuluaga Quintero M, Moreno Gómez L et al (2016) Myasthenia gravis after kidney transplantation. Nefrologia 36:716–718. https://doi.org/10.1016/j.nefro.2016.05.006
doi: 10.1016/j.nefro.2016.05.006
pubmed: 27553988
O’Reilly S, Walshe E, Breathnach A et al (1992) Myasthenia gravis associated with cyclosporin treatment. Nephrol Dial Transplant 7:455
pubmed: 1321387
Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419–425. https://doi.org/10.1212/WNL.0000000000002790
doi: 10.1212/WNL.0000000000002790
pubmed: 27358333
pmcid: 4977114
Bechstein WO (2000) Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 13:313–326. https://doi.org/10.1007/s001470050708
doi: 10.1007/s001470050708
pubmed: 11052266
Senzolo M, Marco S, Ferronato C et al (2009) Neurologic complications after solid organ transplantation. Transpl Int 22:269–278. https://doi.org/10.1111/j.1432-2277.2008.00780.x
doi: 10.1111/j.1432-2277.2008.00780.x
pubmed: 19076332
Mayer AD, Dmitrewski J, Squifflet JP et al (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436–443. https://doi.org/10.1097/00007890-199708150-00012
doi: 10.1097/00007890-199708150-00012
pubmed: 9275110
Pirsch JD, Miller J, Deierhoi MH et al (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63:977–983. https://doi.org/10.1097/00007890-199704150-00013
doi: 10.1097/00007890-199704150-00013
pubmed: 9112351
Margreiter R (2002) Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359:741–746. https://doi.org/10.1016/S0140-6736(02)07875-3
doi: 10.1016/S0140-6736(02)07875-3
pubmed: 11888584
Andrews LM, Li Y, De Winter BCM et al (2017) Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol 13:1225–1236. https://doi.org/10.1080/17425255.2017.1395413
doi: 10.1080/17425255.2017.1395413
pubmed: 29084469
Sánchez Fructuoso A, Ruiz JC, Franco A et al (2020) Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study. Clin Transplant 34:e13767. https://doi.org/10.1111/ctr.13767
doi: 10.1111/ctr.13767
pubmed: 31815310
Langone A, Steinberg SM, Gedaly R et al (2015) Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant 29:796–805. https://doi.org/10.1111/ctr.12581
doi: 10.1111/ctr.12581
pubmed: 26113208
pmcid: 4755036
Rifai K, Kirchner GI, Bahr MJ et al (2006) A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl 12:411–415. https://doi.org/10.1002/lt.20610
doi: 10.1002/lt.20610
pubmed: 16456830
Gulleroglu K, Baskin E, Bayrakci U et al (2013) Sudden hearing loss associated with tacrolimus after pediatric renal transplant. Exp Clin Transplant 11:562–564. https://doi.org/10.6002/ect.2012.0241
doi: 10.6002/ect.2012.0241
pubmed: 24344948
Gulleroglu K, Baskin E, Aydin E et al (2015) Hearing status in pediatric renal transplant recipients. Exp Clin Transplant 13:324–328. https://doi.org/10.6002/ect.2014.0158
doi: 10.6002/ect.2014.0158
pubmed: 25365361
Lakshmi BS, Vidya B, Reddy MHK et al (2020) Sensorineural deafness following tacrolimus use. Exp Clin Transplant 18:110–111. https://doi.org/10.6002/ect.2017.0114
doi: 10.6002/ect.2017.0114
pubmed: 29969081
Bhagavati S, Maccabee P, Muntean E, Sumrani NB (2007) Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients: case reports. Transplant Proc 39:3465–3467. https://doi.org/10.1016/j.transproceed.2007.06.088
doi: 10.1016/j.transproceed.2007.06.088
pubmed: 18089409
Renard D, Gauthier T, Venetz J-P et al (2012) Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J 5:323–326. https://doi.org/10.1093/ckj/sfs067
doi: 10.1093/ckj/sfs067
pubmed: 25874089
pmcid: 4393473
Echaniz-Laguna A, de Séze J, Chanson J-B (2012) Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. J Neurol Neurosurg Psychiatry 83:699–705. https://doi.org/10.1136/jnnp-2012-302374
doi: 10.1136/jnnp-2012-302374
pubmed: 22577230
Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15:1–9. https://doi.org/10.1111/j.1529-8027.2010.00245.x
doi: 10.1111/j.1529-8027.2010.00245.x
Schmidt N, Alloway RR, Walsh RC et al (2012) Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 94:352–361. https://doi.org/10.1097/TP.0b013e318257acf6
doi: 10.1097/TP.0b013e318257acf6
pubmed: 22836132
Fradkin M, Batash R, Elmaleh S et al (2019) Management of peripheral neuropathy induced by chemotherapy. Curr Med Chem 26:4698–4708. https://doi.org/10.2174/0929867326666190107163756
doi: 10.2174/0929867326666190107163756
pubmed: 30621553
Tillmann F-P, Jäger M, Blondin D et al (2008) Post-transplant distal limb syndrome: clinical diagnosis and long-term outcome in 37 renal transplant recipients. Transpl Int 21:547–553. https://doi.org/10.1111/j.1432-2277.2008.00668.x
doi: 10.1111/j.1432-2277.2008.00668.x
pubmed: 18373640
Collini A, De Bartolomeis C, Barni R et al (2006) Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int 70:1367–1370. https://doi.org/10.1038/sj.ki.5001833
doi: 10.1038/sj.ki.5001833
pubmed: 16955101
Mallamaci F, Zoccali C, Ciccarelli M, Briggs JD (1986) Autonomic function in uremic patients treated by hemodialysis or CAPD and in transplant patients. Clin Nephrol 25:175–180
pubmed: 3516480
Solders G, Wilczek H, Gunnarsson R et al (1987) Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study. Lancet 2:1232–1235. https://doi.org/10.1016/s0140-6736(87)91851-4
doi: 10.1016/s0140-6736(87)91851-4
pubmed: 2890854
Solders G, Persson A, Wilczek H (1986) Autonomic system dysfunction and polyneuropathy in nondiabetic uremia. A one-year follow-up study after renal transplantation. Transplantation 41:616–619. https://doi.org/10.1097/00007890-198605000-00013
doi: 10.1097/00007890-198605000-00013
pubmed: 3518166
Robinson TG, Carr SJ (2002) Cardiovascular autonomic dysfunction in uremia. Kidney Int 62:1921–1932. https://doi.org/10.1046/j.1523-1755.2002.00659.x
doi: 10.1046/j.1523-1755.2002.00659.x
pubmed: 12427117
Minetto MA, D’Angelo V, Arvat E, Kesari S (2018) Diagnostic work-up in steroid myopathy. Endocrine 60:219–223. https://doi.org/10.1007/s12020-017-1472-5
doi: 10.1007/s12020-017-1472-5
pubmed: 29143179
Townamchai N, Safa K, Chandraker A (2013) Immunologic monitoring in kidney transplant recipients. Kidney Res Clin Pract 32:52–61. https://doi.org/10.1016/j.krcp.2013.04.002
doi: 10.1016/j.krcp.2013.04.002
pubmed: 26877913
pmcid: 4713911
Li X, Ishida H, Yamaguchi Y, Tanabe K (2008) Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Transpl Int 21:1145–1152. https://doi.org/10.1111/j.1432-2277.2008.00755.x
doi: 10.1111/j.1432-2277.2008.00755.x
pubmed: 18803618
van Besouw NM, van der Mast BJ, de Kuiper P et al (2000) Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 70:136–143
pubmed: 10919590
Zitzner JR, Tambur AR (2012) Role of ELISPOT assays in risk assessment pre- and post-kidney transplantation. Cells 1:100–110. https://doi.org/10.3390/cells1020100
doi: 10.3390/cells1020100
pubmed: 24710417
pmcid: 3901086
Ravaioli M, Neri F, Lazzarotto T et al (2015) Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial. Transplantation 99:1625–1632. https://doi.org/10.1097/TP.0000000000000650
doi: 10.1097/TP.0000000000000650
pubmed: 25757214
Mian M, Natori Y, Ferreira V et al (2018) Evaluation of a novel global immunity assay to predict infection in organ transplant recipients. Clin Infect Dis 66:1392–1397. https://doi.org/10.1093/cid/cix1008
doi: 10.1093/cid/cix1008
pubmed: 29281051
Doberer K, Schiemann M, Strassl R et al (2020) Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—a prospective observational trial. Am J Transplant 20:2081–2090. https://doi.org/10.1111/ajt.15810
doi: 10.1111/ajt.15810
pubmed: 32034850
pmcid: 7496119
Frasca D, Blomberg BB (2016) Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology 17:7–19. https://doi.org/10.1007/s10522-015-9578-8
doi: 10.1007/s10522-015-9578-8
pubmed: 25921609
Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33–60. https://doi.org/10.2165/00003088-200544010-00002
doi: 10.2165/00003088-200544010-00002
pubmed: 15634031
Traitanon O, Mathew JM, Shetty A et al (2019) Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil. PLoS ONE 14:e0216300. https://doi.org/10.1371/journal.pone.0216300
doi: 10.1371/journal.pone.0216300
pubmed: 31136582
pmcid: 6538151